Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 December 2024 | Story Dr Cindé Greyling | Photo Kaleidoscope
MACE Winners 2024
From left to right: Burneline Kaars (Head: Employee Wellness and Organisational Development), Dr WP Wahl (Student Life Director), Linda Greyling (Senior Officer: Special Projects, Student Recruitment Services), Gerben Van Niekerk (Senior Officer: Kovsie Support Services), Malia Maranyane (Senior Officer: Undergraduate Marketing, Student Recruitment Services), Nomonde Mbadi (Student Recruitment Services Director), and Susan Van Jaarsveld (Senior Director: Human Resources).

On 28 November 2024, the University of the Free State (UFS) did it again – reigned as champions at the annual Marketing, Advancement and Communication in Education (MACE) Excellence Awards and walking away with two of the top awards: the MACE Award for Outstanding Research and the Severus Cerff Award for Consistent Excellence.

KovsieX was named the overall winner of the MACE Award for Outstanding Research. This award is made to the entry with the highest score in research, clearly demonstrating how research has supported the strategic objectives of the institution and the project. KovsieX is a multiplatform approach designed to leverage the strengths of diverse media channels. This digitalisation aligns with Vision 130, leveraging emerging technologies to enhance teaching and learning quality and efficiency of non-academic support structures and systems.

The UFS’ entries were of such high quality that the university won the sought-after Severus Cerff Award for Consistent Excellence. This award is based on the number of entries entered by an institution and the number and level of those entries winning awards. The award is therefore made to the institution with the highest success ratio.

Furthermore, the UFS Matriculant of the Year event received a Silver Award – entries scoring 5.75 or higher earn a Silver Award, placing this event among some of the top achievers in the events category. Three UFS entries received Gold Awards and were the winners in their respective categories: KovsieChat (Digital Channels), 2024 Women’s Day Breakfast (Events), and KovsieX (Stakeholder Engagement Campaigns). This is a magnificent achievement for the UFS.

"Winning a MACE award at this early stage is proof that KovsieX is not just meeting national standards – it’s setting them. If we can achieve this level of excellence now, imagine how we’ll compete on the global stage when the project is fully realised,” says Gerben van Niekerk, Student Media Manager.

Lacea Loader, Senior Director: Communication and Marketing and Coordinator of the MACE Excellence Awards, explained that a record number of entries were received for the Excellence Awards this year. “We are ecstatic about the direction of communication at the UFS and that the university has been able to maintain the quality of its entries in recent years,” says Loader.

The MACE Excellence Awards takes place annually as part of the MACE National Conference, recognising and celebrating excellence and the achievements of specialists and practitioners in marketing, advancement, and communication in the higher-education sector. This year, the Cape Peninsula University of Technology (CPUT) hosted the conference from 27 to 28 November 2024.

In 2023, the UFS won 11 awards, including the Chairperson’s Award of Excellence. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept